Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Receivables (2016 - 2025)

Altimmune (ALT) has disclosed Receivables for 16 consecutive years, with $1.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Receivables rose 112.23% to $1.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.5 million, a 112.23% increase, with the full-year FY2024 number at $944000.0, down 22.05% from a year prior.
  • Receivables was $1.5 million for Q3 2025 at Altimmune, up from $321000.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $4.8 million in Q1 2021 to a low of $136000.0 in Q2 2023.
  • A 5-year average of $1.1 million and a median of $724000.0 in 2024 define the central range for Receivables.
  • Peak YoY movement for Receivables: tumbled 95.98% in 2022, then skyrocketed 600.0% in 2023.
  • Altimmune's Receivables stood at $429000.0 in 2021, then plummeted by 59.67% to $173000.0 in 2022, then surged by 600.0% to $1.2 million in 2023, then dropped by 22.05% to $944000.0 in 2024, then surged by 63.67% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for ALT's Receivables are $1.5 million (Q3 2025), $321000.0 (Q2 2025), and $907000.0 (Q1 2025).